Effectiveness and comparison of reteplase versus streptokinase thrombolytic agents in the patients of acute myocardial infarction

2016-11-19T08-05-21Z
Source: International Journal of Medical Science and Public Health
Sunil Kumar Goel, Ishita Goel, Sandeep Agarwal.
Background: Streptokinase and reteplase are commonly used for thrombolytic therapy in the patients with acute myocardial infarction (AMI). A comparative study was designed to evaluate the effectiveness of both thrombolytic agents. Objective: The objective of this study was to compare the effectiveness, reperfusion rates, mortality, and safety profile of two thrombolytics (reteplase and streptokinase) in the patients of AMI. Materials and Methods: The effectiveness of both thrombolytics (reteplase and streptokinase) was compared on AMI patients during hospital stay, at 1-month and 1-year follow-up. The difference of both groups was assessed by Chi-square and Students t-test wherever required. Results: A total of 414 patients of AMI were included in the study. No significant difference was apparent between the effectiveness of both thrombolytics agents at 1-month follow-up of AMI patients. Patients thrombolysed with reteplase showed a significantly low mortality (χ2 = 3.96, d.f. = 1, P = 0.0466) at 1-year post-AMI follow-up. The mean age of patients of reteplase group was 56.7 ± 4.95 years and for patients of streptokinase was 53.2 ± 9.19 years (P

http://ift.tt/2g8j4KH